Monday, 10 July 2017, 6:30pm CEST

We kindly invite investors and analysts to participate in an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017.

During the briefing, Roche will discuss new data for emicizumab (ACE910) in hemophilia A:

HAVEN1 - phase 3 study of emicizumab (ACE910) prophylaxis in persons with hemophilia A with inhibitors

HAVEN2 - phase 3 study of emicizumab (ACE910) in pediatric persons with hemophilia A with inhibitors

Venue

Hotel Berlin, Berlin
Lützowplatz 17
10785 Berlin
Germany
map

Date/Time

Monday, 10 July 2017 @ 6:30pm CEST
The briefing will be followed by a buffet reception.

An invitation with the detailed programme and registration form will follow shortly.

Best regards,

Karl Mahler
Head of Investor Relations

Sabine Borngräber
Investor Relations Officer

get the latest news and updates to your inbox.